80 related articles for article (PubMed ID: 10408416)
1. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer.
Ercoli A; Ferrandina G; Raspaglio G; Marone M; Maggiano N; Del Mastro P; Benedetti Panici P; Mancuso S; Scambia G
Br J Cancer; 1999 Jul; 80(10):1665-71. PubMed ID: 10408416
[TBL] [Abstract][Full Text] [Related]
2. [Expression of mismatch repair gene hMSH2 in human malignant ovarian tumors and its clinical significance].
Ma L; Zhang J; Peng Z
Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):291-3. PubMed ID: 11775911
[TBL] [Abstract][Full Text] [Related]
3. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
[TBL] [Abstract][Full Text] [Related]
4. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.
Leach FS; Velasco A; Hsieh JT; Sagalowsky AI; McConnell JD
J Urol; 2000 Nov; 164(5):1830-3. PubMed ID: 11025778
[TBL] [Abstract][Full Text] [Related]
5. Loss of hMSH2 expression in primary breast cancer with p53 alterations.
Spagnoletti I; Pizzi C; Galietta A; Di Maio M; Mastranzo P; Daniele S; Limite G; Pettinato G; Contegiacomo A
Oncol Rep; 2004 Apr; 11(4):845-51. PubMed ID: 15010883
[TBL] [Abstract][Full Text] [Related]
6. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.
Dutta T; Sharma H; Kumar L; Dinda AK; Kumar S; Bhatla N; Singh N
Cancer Chemother Pharmacol; 2005 Oct; 56(4):427-35. PubMed ID: 15906030
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
11. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder.
Mylona E; Zarogiannos A; Nomikos A; Giannopoulou I; Nikolaou I; Zervas A; Nakopoulou L
APMIS; 2008 Jan; 116(1):59-65. PubMed ID: 18254781
[TBL] [Abstract][Full Text] [Related]
15. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
[TBL] [Abstract][Full Text] [Related]
17. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
18. [Expression of hMSH2 gene in esophageal cancer].
Zhang GY; Liu QL; Ma CX; Le XP; Ge XF; Ding Y; Zhang QX
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jun; 24(6):662-4, 669. PubMed ID: 15201084
[TBL] [Abstract][Full Text] [Related]
19. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
20. Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma.
Hamid AA; Mandai M; Konishi I; Nanbu K; Tsuruta Y; Kusakari T; Kariya M; Kita M; Fujii S
Cancer; 2002 Feb; 94(4):997-1005. PubMed ID: 11920468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
